Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward A Ashton

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Discovery|March 15, 2013
Widespread functional and molecular imaging in drug developmentEdward A Ashton
Journal of Magnetic Resonance Imaging : JMRI|February 21, 2003
Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRIEdward A Ashton, Chihiro Takahashi, Michel J Berg, et al.
AJR. American Journal of Roentgenology|January 23, 2010
Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responsesChaan S Ng, David L Raunig, Edward F Jackson, et al.
American Journal of Clinical Oncology|March 26, 2016
Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II TrialVenkata K Pokuri, Garin M Tomaszewski, Sihem Ait-Oudhia, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2011
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumorsAlejandro D Ricart, Edward A Ashton, Matthew M Cooney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I studyGlenn Liu, Hope S Rugo, George Wilding, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Discovery|March 15, 2013
Widespread functional and molecular imaging in drug developmentEdward A Ashton
Journal of Magnetic Resonance Imaging : JMRI|February 21, 2003
Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRIEdward A Ashton, Chihiro Takahashi, Michel J Berg, et al.
AJR. American Journal of Roentgenology|January 23, 2010
Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responsesChaan S Ng, David L Raunig, Edward F Jackson, et al.
American Journal of Clinical Oncology|March 26, 2016
Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II TrialVenkata K Pokuri, Garin M Tomaszewski, Sihem Ait-Oudhia, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2011
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumorsAlejandro D Ricart, Edward A Ashton, Matthew M Cooney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I studyGlenn Liu, Hope S Rugo, George Wilding, et al.
Pageof 1